Is It Too Late To Consider Syndax Pharmaceuticals (SNDX) After A 116% One-Year Surge?

Simply Wall St.04-15

To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627422548?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-15 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627422548","market":"sg","top_or_hot":-1,"title":"Is It Too Late To Consider Syndax Pharmaceuticals (SNDX) After A 116% One-Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-too-late-to-consider-syndax-pharmaceuticals-sndx-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Syndax Pharmaceuticals (SNDX) After A 116% One-Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Syndax Pharmaceuticals (SNDX) After A 116% One-Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-15 04:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-too-late-to-consider-syndax-pharmaceuticals-sndx-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-too-late-to-consider-syndax-pharmaceuticals-sndx-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-too-late-to-consider-syndax-pharmaceuticals-sndx-after","article_id":"2627422548","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-too-late-to-consider-syndax-pharmaceuticals-sndx-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627422548","pubTimestamp":1776197519,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation measures.\nThe shares last closed at US$24.25, with returns of 3.2% over 30 days, 13.8% year to date and 115.7% over the past year. This naturally raises questions about whether expectations or risk perceptions have shifted.\nRecent coverage has focused on Syndax Pharmaceuticals as part of the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. ","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技"},"translate_title":"Syndax Pharmaceuticals(SNDX)一年飙升116%后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1.5,"DCF":1},"content_text":"To move beyond the headline moves in Syndax Pharmaceuticals and really understand whether the current share price offers value, you need to look at how the stock compares on a few different valuation measures. The shares last closed at US$24.25, with returns of 3.2% over 30 days, 13.8% year to date and 115.7% over the past year. This naturally raises questions about whether expectations or risk perceptions have shifted. Recent coverage has focused on Syndax Pharmaceuticals as part of the broader interest in US biotech names, with investors weighing company specific developments against sector wide sentiment. This has helped frame the recent price performance within a context of active capital flows into higher risk, research driven businesses. Simply Wall St currently gives Syndax Pharmaceuticals a value score of 3/6. The rest of this article will break down what that means across different valuation methods, then finish with a more complete way to think about value that goes beyond any single metric. Syndax Pharmaceuticals delivered 115.7% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Syndax Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and discounting them back to today in dollar terms. For Syndax Pharmaceuticals, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. The latest twelve month free cash flow is a loss of $323.37 million. Analyst inputs and subsequent extrapolations point to free cash flow of $326.9 million by 2030. Within that, specific projections run from $49 million of free cash flow in 2026 to $441.22 million in 2035, with discounting applied each year to reflect the time value of money and risk. On this basis, the DCF model arrives at an estimated intrinsic value of US$84.40 per share. Compared with the recent share price of US$24.25, the model output points to the stock trading at a 71.3% discount to this estimate. This is a large gap for readers to weigh against their own expectations and risk tolerance. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Syndax Pharmaceuticals is undervalued by 71.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks. SNDX Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Syndax Pharmaceuticals. Approach 2: Syndax Pharmaceuticals Price vs Sales For companies that are still building profitability, the P/S ratio is often a practical way to think about value because it compares the share price with the revenue the business is already generating, rather than relying on earnings that might be negative or volatile. In general, higher growth expectations and lower perceived risk can support a higher P/S multiple, while slower growth or higher risk tends to justify a lower multiple. That is why simply comparing P/S ratios across companies without context can be misleading. Syndax Pharmaceuticals currently trades on a P/S of 12.41x. This sits slightly above the Biotechs industry average of 11.30x, but below the peer group average of 15.23x. Simply Wall St also calculates a proprietary Fair Ratio of 1.78x, which reflects factors such as earnings growth, industry, profit margin, market cap and specific risks. The Fair Ratio aims to be more tailored than a straight comparison with peers or the broad industry because it adjusts for the company’s own growth profile, risk characteristics and size. Set against the current 12.41x P/S, the Fair Ratio suggests Syndax Pharmaceuticals trades at a richer multiple than would typically be expected on this framework. Result: OVERVALUED NasdaqGS:SNDX P/S Ratio as at Apr 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Syndax Pharmaceuticals Narrative Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you attach your own story about Syndax Pharmaceuticals to the numbers by linking your view of its future revenue, earnings and margins to a forecast. This then translates into a Fair Value you can compare with the current share price, updates automatically when fresh news or earnings arrive, and can look very different from other investors. For example, one bearish Narrative on the Community page currently pins Fair Value at US$28.00, while a more optimistic Narrative sits at US$56.00. This gives you a clear sense of how different assumptions about the same business lead to very different conclusions on whether the current US$24.25 price looks high, low or somewhere in between. Do you think there's more to the story for Syndax Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:SNDX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627422548","isCrawlerRequest":true}